Centeon to purchase Delta Biotechnology for $45 mil. in cash, acquire recombinant human albumin technology.
CENTEON TO PURCHASE DELTA BIOTECHNOLOGY FOR $45 MIL. in cash over a period of two years from Ohmeda, the health care business of the BOC Group. The acquisition of Nottingham, England-based Delta gives the Hoechst AG/Rhone-Poulenc Rorer joint venture Centeon the technology to develop recombinant human albumin as an extension of the company's plasma protein therapies. Centeon is a supplier of human albumin for plasma replacement therapy during surgery and in the treatment of shocks and burns.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth